questionsmedicales.fr
Facteurs biologiques
Toxines biologiques
Toxines bactériennes
Endotoxines
Endotoxines : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Tests de laboratoire
Endotoxines
Culture bactérienne
Endotoxines
Symptômes
5
Système immunitaire
Choc septique
Choc septique
Hypotension
Prévention
5
Sécurité en laboratoire
Équipements de protection
Infections nosocomiales
Hygiène hospitalière
Traitements
5
Antibiotiques
Soins de soutien
Corticostéroïdes
Inflammation
Choc septique
Vasopresseurs
Antidotes
Traitement symptomatique
Prise en charge précoce
Complications
Complications
5
Choc septique
Insuffisance organique
Défaillance organique
Inflammation
Syndrome de détresse respiratoire
Inflammation pulmonaire
Dommages neurologiques
Inflammation systémique
Facteurs de risque
5
Facteurs de risque
Immunodépression
Infections bactériennes
Gram-négatif
Interventions chirurgicales
Infections
Diabète
Système immunitaire
Conditions de vie
Bactéries
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Endotoxines : Questions médicales les plus fréquentes",
"headline": "Endotoxines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Endotoxines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-12",
"dateModified": "2025-05-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Endotoxines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Toxines bactériennes",
"url": "https://questionsmedicales.fr/mesh/D001427",
"about": {
"@type": "MedicalCondition",
"name": "Toxines bactériennes",
"code": {
"@type": "MedicalCode",
"code": "D001427",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.946.123"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Lipopolysaccharides",
"alternateName": "Lipopolysaccharides",
"url": "https://questionsmedicales.fr/mesh/D008070",
"about": {
"@type": "MedicalCondition",
"name": "Lipopolysaccharides",
"code": {
"@type": "MedicalCode",
"code": "D008070",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.946.123.329.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Lipide A",
"alternateName": "Lipid A",
"url": "https://questionsmedicales.fr/mesh/D008050",
"about": {
"@type": "MedicalCondition",
"name": "Lipide A",
"code": {
"@type": "MedicalCode",
"code": "D008050",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.946.123.329.500.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Antigènes O",
"alternateName": "O Antigens",
"url": "https://questionsmedicales.fr/mesh/D019081",
"about": {
"@type": "MedicalCondition",
"name": "Antigènes O",
"code": {
"@type": "MedicalCode",
"code": "D019081",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.946.123.329.500.600"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Endotoxines",
"alternateName": "Endotoxins",
"code": {
"@type": "MedicalCode",
"code": "D004731",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Johannes Reich",
"url": "https://questionsmedicales.fr/author/Johannes%20Reich",
"affiliation": {
"@type": "Organization",
"name": "Microcoat Biotechnologie GmbH, Am Neuland 3, 82347 Bernried am Stanberger See, Germany. j.reich@microcoat.de."
}
},
{
"@type": "Person",
"name": "Guy C Brown",
"url": "https://questionsmedicales.fr/author/Guy%20C%20Brown",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, UK. gcb3@cam.ac.uk."
}
},
{
"@type": "Person",
"name": "John A Kellum",
"url": "https://questionsmedicales.fr/author/John%20A%20Kellum",
"affiliation": {
"@type": "Organization",
"name": "Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."
}
},
{
"@type": "Person",
"name": "Gary Hannon",
"url": "https://questionsmedicales.fr/author/Gary%20Hannon",
"affiliation": {
"@type": "Organization",
"name": "Nanomedicine and Molecular Imaging Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, Dublin, Ireland."
}
},
{
"@type": "Person",
"name": "Adriele Prina-Mello",
"url": "https://questionsmedicales.fr/author/Adriele%20Prina-Mello",
"affiliation": {
"@type": "Organization",
"name": "Nanomedicine and Molecular Imaging Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, Dublin, Ireland."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Azacitidine (Vidaza",
"datePublished": "2023-09-11",
"url": "https://questionsmedicales.fr/article/37695474",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s40272-023-00588-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Safety Signal between Azacitidine and Pericarditis.",
"datePublished": "2022-08-18",
"url": "https://questionsmedicales.fr/article/35981518",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000526610"
}
},
{
"@type": "ScholarlyArticle",
"name": "G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial.",
"datePublished": "2022-07-07",
"url": "https://questionsmedicales.fr/article/35798720",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41408-022-00698-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.",
"datePublished": "2023-01-14",
"url": "https://questionsmedicales.fr/article/36641501",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12185-023-03532-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Azacitidine and its role in the upfront treatment of acute myeloid leukemia.",
"datePublished": "2022-06-13",
"url": "https://questionsmedicales.fr/article/35695017",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14656566.2022.2082284"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Toxines biologiques",
"item": "https://questionsmedicales.fr/mesh/D014118"
},
{
"@type": "ListItem",
"position": 4,
"name": "Toxines bactériennes",
"item": "https://questionsmedicales.fr/mesh/D001427"
},
{
"@type": "ListItem",
"position": 5,
"name": "Endotoxines",
"item": "https://questionsmedicales.fr/mesh/D004731"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Endotoxines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Endotoxines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Endotoxines",
"description": "Comment diagnostiquer une intoxication par endotoxines ?\nQuels tests sont utilisés pour détecter les endotoxines ?\nQuels signes cliniques indiquent une exposition aux endotoxines ?\nLes endotoxines peuvent-elles être détectées dans le sang ?\nQuel rôle joue la culture bactérienne dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Azacitidine#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Endotoxines",
"description": "Quels sont les symptômes d'une intoxication par endotoxines ?\nComment les endotoxines affectent-elles le système immunitaire ?\nLes endotoxines causent-elles des douleurs ?\nQuels signes indiquent un choc septique dû aux endotoxines ?\nLes symptômes varient-ils selon l'exposition ?",
"url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Azacitidine#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Endotoxines",
"description": "Comment prévenir l'exposition aux endotoxines ?\nLes vaccins peuvent-ils prévenir les infections à endotoxines ?\nQuelles mesures de sécurité en laboratoire sont nécessaires ?\nLes antibiotiques préventifs sont-ils efficaces ?\nComment réduire le risque d'infections nosocomiales ?",
"url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Azacitidine#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Endotoxines",
"description": "Quel est le traitement principal pour une intoxication par endotoxines ?\nLes corticostéroïdes sont-ils efficaces contre les endotoxines ?\nComment traiter le choc septique causé par des endotoxines ?\nLes antidotes existent-ils pour les endotoxines ?\nQuelle est l'importance de la prise en charge précoce ?",
"url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Azacitidine#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Endotoxines",
"description": "Quelles sont les complications possibles d'une intoxication par endotoxines ?\nComment les endotoxines affectent-elles les organes ?\nLe syndrome de détresse respiratoire est-il lié aux endotoxines ?\nLes endotoxines peuvent-elles causer des dommages neurologiques ?\nQuel est le pronostic après une exposition aux endotoxines ?",
"url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Azacitidine#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Endotoxines",
"description": "Quels sont les principaux facteurs de risque d'intoxication par endotoxines ?\nLes infections bactériennes augmentent-elles le risque d'endotoxines ?\nLes interventions chirurgicales augmentent-elles le risque ?\nLe diabète est-il un facteur de risque pour les endotoxines ?\nLes conditions de vie insalubres augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Azacitidine#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une intoxication par endotoxines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins, cultures et évaluation clinique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les endotoxines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le test de limule et les tests ELISA sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent une exposition aux endotoxines ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, frissons, hypotension et tachycardie sont des signes fréquents."
}
},
{
"@type": "Question",
"name": "Les endotoxines peuvent-elles être détectées dans le sang ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests spécifiques peuvent détecter les endotoxines dans le sang."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la culture bactérienne dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet d'identifier la source bactérienne des endotoxines."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une intoxication par endotoxines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fièvre, frissons, douleurs abdominales et confusion."
}
},
{
"@type": "Question",
"name": "Comment les endotoxines affectent-elles le système immunitaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles provoquent une réponse inflammatoire excessive, pouvant mener à un choc."
}
},
{
"@type": "Question",
"name": "Les endotoxines causent-elles des douleurs ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent provoquer des douleurs abdominales et musculaires."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent un choc septique dû aux endotoxines ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Hypotension, tachycardie, confusion et peau froide sont des signes clés."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'exposition ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité des symptômes dépend de la dose et de la durée d'exposition."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'exposition aux endotoxines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les environnements contaminés et respecter les protocoles d'hygiène."
}
},
{
"@type": "Question",
"name": "Les vaccins peuvent-ils prévenir les infections à endotoxines ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de vaccin spécifique contre les endotoxines, mais contre certaines bactéries."
}
},
{
"@type": "Question",
"name": "Quelles mesures de sécurité en laboratoire sont nécessaires ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des équipements de protection individuelle et des procédures de désinfection."
}
},
{
"@type": "Question",
"name": "Les antibiotiques préventifs sont-ils efficaces ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être utilisés dans certains cas à risque, mais pas systématiquement."
}
},
{
"@type": "Question",
"name": "Comment réduire le risque d'infections nosocomiales ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Améliorer l'hygiène hospitalière et le contrôle des infections est essentiel."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal pour une intoxication par endotoxines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut des antibiotiques et des soins de soutien pour stabiliser le patient."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils efficaces contre les endotoxines ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent réduire l'inflammation, mais leur utilisation est controversée."
}
},
{
"@type": "Question",
"name": "Comment traiter le choc septique causé par des endotoxines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement nécessite des fluides intraveineux et des vasopresseurs."
}
},
{
"@type": "Question",
"name": "Les antidotes existent-ils pour les endotoxines ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas d'antidote spécifique, le traitement est symptomatique."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la prise en charge précoce ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une prise en charge rapide améliore les chances de survie et réduit les complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles d'une intoxication par endotoxines ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent le choc septique, l'insuffisance organique et la mort."
}
},
{
"@type": "Question",
"name": "Comment les endotoxines affectent-elles les organes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent provoquer une défaillance multi-organique en raison de l'inflammation."
}
},
{
"@type": "Question",
"name": "Le syndrome de détresse respiratoire est-il lié aux endotoxines ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'inflammation pulmonaire peut entraîner un syndrome de détresse respiratoire."
}
},
{
"@type": "Question",
"name": "Les endotoxines peuvent-elles causer des dommages neurologiques ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent provoquer des troubles neurologiques en raison de l'inflammation systémique."
}
},
{
"@type": "Question",
"name": "Quel est le pronostic après une exposition aux endotoxines ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le pronostic dépend de la rapidité du traitement et de la gravité de l'exposition."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque d'intoxication par endotoxines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients immunodéprimés, les personnes âgées et les hospitalisés sont à risque."
}
},
{
"@type": "Question",
"name": "Les infections bactériennes augmentent-elles le risque d'endotoxines ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections par des bactéries Gram-négatives sont un facteur de risque majeur."
}
},
{
"@type": "Question",
"name": "Les interventions chirurgicales augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les interventions chirurgicales peuvent exposer à des endotoxines, surtout en cas d'infection."
}
},
{
"@type": "Question",
"name": "Le diabète est-il un facteur de risque pour les endotoxines ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète peut affaiblir le système immunitaire et augmenter le risque d'infections."
}
},
{
"@type": "Question",
"name": "Les conditions de vie insalubres augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles favorisent la prolifération bactérienne et l'exposition aux endotoxines."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 07/05/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Microcoat Biotechnologie GmbH, Am Neuland 3, 82347 Bernried am Stanberger See, Germany. j.reich@microcoat.de.
Publications dans "Endotoxines" :
3 publications dans cette catégorie
Affiliations :
Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, UK. gcb3@cam.ac.uk.
Publications dans "Endotoxines" :
3 publications dans cette catégorie
Affiliations :
Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Spectral Medical Inc., Toronto, Ontario, Canada.
Publications dans "Endotoxines" :
2 publications dans cette catégorie
Affiliations :
Nanomedicine and Molecular Imaging Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, Dublin, Ireland.
Laboratory of Biological Characterization of Advanced Materials (LBCAM), Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland.
Publications dans "Endotoxines" :
2 publications dans cette catégorie
Affiliations :
Nanomedicine and Molecular Imaging Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, Dublin, Ireland.
Laboratory of Biological Characterization of Advanced Materials (LBCAM), Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland.
Advanced Materials and Bioengineering Research (AMBER) Centre, CRANN institute, Trinity College Dublin, Dublin, Ireland.
Publications dans "Endotoxines" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Biophotonics and Advanced Microscopy, Institute of Biochemistry and Cell Biology (IBBC), National Research Council (CNR), Napoli, Italy.
Publications dans "Endotoxines" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Biophotonics and Advanced Microscopy, Institute of Biochemistry and Cell Biology (IBBC), National Research Council (CNR), Napoli, Italy.
Publications dans "Endotoxines" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Innate Immunity, Inflammation and Immuno-nanosafety, IBBC-CNR, Napoli, Italy.
Publications dans "Endotoxines" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Innate Immunity, Inflammation and Immuno-nanosafety, IBBC-CNR, Napoli, Italy.
Publications dans "Endotoxines" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Biophotonics and Advanced Microscopy, Institute of Biochemistry and Cell Biology (IBBC), National Research Council (CNR), Napoli, Italy.
Publications dans "Endotoxines" :
2 publications dans cette catégorie
Affiliations :
Toray Medical Co., Ltd., Tokyo, Japan.
Publications dans "Endotoxines" :
2 publications dans cette catégorie
Affiliations :
Microbial Solutions, Charles River Laboratories, 1023 Wappoo Road, Suite 43-B, Charleston, SC 29407, United States.
Publications dans "Endotoxines" :
2 publications dans cette catégorie
Affiliations :
Department of Chemical and Biochemical Engineering, Missouri University of Science and Technology, Rolla, Missouri.
Publications dans "Endotoxines" :
2 publications dans cette catégorie
Affiliations :
Department of Chemical and Biochemical Engineering, Missouri University of Science and Technology, Rolla, Missouri.
Publications dans "Endotoxines" :
2 publications dans cette catégorie
Affiliations :
Department of Occupational and Environmental Health, University of Iowa, Iowa City, IA, United States.
Publications dans "Endotoxines" :
2 publications dans cette catégorie
Affiliations :
Department of Occupational and Environmental Health, University of Iowa, Iowa City, IA, United States.
Publications dans "Endotoxines" :
1 publication dans cette catégorie
Affiliations :
Microcoat Biotechnologie GmbH, Am Neuland 3, 82347 Bernried am Stanberger See, Germany. f.weyer@microcoat.de.
Publications dans "Endotoxines" :
1 publication dans cette catégorie
Affiliations :
LPS (Laboratory Program Support) Consulting Office, Tokyo 160-0023, Japan. htamura@lpsct.com.
Department of Host Defense and Biochemical Research, Juntendo University Graduate School of Medicine, Tokyo 113-8431, Japan. htamura@lpsct.com.
Publications dans "Endotoxines" :
1 publication dans cette catégorie
Affiliations :
Department of Host Defense and Biochemical Research, Juntendo University Graduate School of Medicine, Tokyo 113-8431, Japan. nagaokai@juntendo.ac.jp.
Publications dans "Endotoxines" :
1 publication dans cette catégorie
Affiliations :
Institute of Physical and Theoretical Chemistry, University of Regensburg, 93040 Regensburg, Germany. Hubert.Motschmann@chemie.uni-regensburg.de.
Publications dans "Endotoxines" :
Advanced myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) are rare hematological malignancies in children. A second allograft is recommended if a relapse occurs after hematop...
We conducted a phase I/II multicenter study to evaluate the safety, pharmacokinetics, and activity of azacitidine in children with relapsed MDS/JMML prior to the second hematopoietic stem cell transpl...
Patients enrolled from June 2013 to March 2019 received azacitidine intravenously/subcutaneously once daily on days 1-7 of a 28-day cycle. The MDS and JMML cohorts followed a two-stage design separate...
Six patients with MDS and four patients with JMML received a median of three and five cycles, respectively. Azacitidine 75 mg/m...
Azacitidine 75 mg/m...
EudraCT 2010-022235-10....
Drug-induced pericarditis is an important cause of pericarditis and if unnoticed and unmanaged can lead to constrictive pericarditis, pericardial effusion, and cardiac tamponade....
The objective of this analysis was to determine if a significant signal exists between azacitidine use and pericarditis....
A pharmacovigilance analysis was performed using the FDA Adverse Event Database....
48 reports of azacitidine-induced pericarditis with azacitidine as the suspect drug were identified. The most common indications for azacitidine use in the adverse event reports were myelodysplastic s...
The signal between azacitidine and pericarditis was found to be statistically significant. Clinicians should be aware of the possible risk of pericarditis when prescribing azacitidine. If there is sus...
GA trial is registered under EudraCT#: 2013-001639-38....
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is caused by UBA1 somatic mutations and is characterized by late-onset systemic autoimmune inflammation and blood abnormalitie...
Acute myeloid leukemia (AML) predominantly affects elderly population. This poses challenges in management, as patients are frequently not candidates for intensive therapy given comorbidities or frail...
We review the mechanism of action, pharmacology, clinical efficacy, and safety of AZA. It reviews current combination therapies of AZA with other targeted therapies for the treatment of newly diagnose...
AZA is a cornerstone for the treatment of patients considered ineligible for intensive chemotherapy induction, but better results and therapies are required for these patients. AZA has shown synergist...
Azacitidine (AZA), a demethylating agent, is one of the mainstay treatments for patients with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) who are ineligible for curative allogene...
We present a retrospective overview of a clinical case of a 71-year-old patient that developed new cytopenias on a background of Chronic Lymphocytic Leukaemia and was diagnosed with therapy-associated...
Arthrocentesis of the knee revealed reactive arthritis with no crystal or organism growth. His symptoms were managed effectively with conservative management including NSAIDs, analgesia and temporary ...
We report a case that points to AZA as a probable cause of arthritis flares in MDS patients. The current limitation of this study is the lack of available data, future reviews and research will aid in...
Myeloproliferative neoplasms in blastic phase (MPN-BP) have a dreadful prognosis. We report the characteristics and outcomes of five MPN-BP patients treated with a never-before-described combination o...
Bone marrow fibrosis in myelodysplastic syndromes (MDS) has been associated with poor outcome. However, these studies were conducted prior to the widespread use of azacitidine in the management of MDS...
Hypomethylating therapies using decitabine or azacitidine are actively investigated to treat acute myeloid leukemia, myelodysplastic syndromes, as maintenance therapy after allogenic stem cell transpl...
Thrombocytopenia, prevalent in the majority of patients with myeloid malignancies, such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), is an independent adverse prognostic factor. ...